Chugai Pharmaceutical
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Chugai Pharmaceutical sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
Chugai Pharmaceutical: 17 sponsored US clinical trials, 4 recruiting.
Chugai Pharmaceutical sponsors 17 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 9 completed. 0 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Celiac Disease, with 2 trials.
Top-decile sponsor footprint
Chugai Pharmaceutical ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
17 total, page 1 of 1
Study of DONQ52 in Active Celiac Disease
NCT07239336
Study of AUBE00 in Patients With Solid Tumors
NCT07030959
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
NCT05907980
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
NCT04511845
A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors
NCT05735366
A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study)
NCT05686369
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
NCT05425446
A Dose-escalation Study of LUNA18 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
NCT05012618
A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism
NCT04209179
A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
NCT02965053
A Study of ERY974 in Patient With Advanced Solid Tumors
NCT02748837
A Single Ascending Dose Study of PCO371 in Healthy Volunteers
NCT02475616
A Phase 2 Study of CIM331 for Atopic Dermatitis Patients
NCT01986933
Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
NCT00976170
A Phase I Study of GC33 in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)
NCT00746317
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
NCT00060138
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Chugai Pharmaceutical pipeline
4 recruiting of 17 indexed (24% open); 9 completed (53%).
Phase mix: 0 late (III/IV) vs 16 early (I/II) (early-phase heavy).
Top condition: Celiac Disease (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Chugai Pharmaceutical: open-pipeline peers nationwide
Peers matched on 17 registered trials and 24% open enrollment, not the therapeutic-area sidebar.
Chugai Pharmaceutical sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 trials (± recruiting share)
- Achieve Life Sciences · 17 trials · 0% recruiting
- BioDelivery Sciences International · 17 trials · 6% recruiting
- ConvaTec · 17 trials · 18% recruiting
- Durham VA Medical Center · 17 trials · 6% recruiting
Sponsors near 24% open enrollment (± trial volume)
- HALEON · 24% recruiting · 34 trials
- Oncotherapeutics · 24% recruiting · 17 trials
- Scripps Whittier Diabetes Institute · 24% recruiting · 17 trials
- The Mind Research Network · 24% recruiting · 17 trials
Related
What to do with this Chugai Pharmaceutical page
17 registered trials is a research-attention snapshot, not an endorsement of Chugai Pharmaceutical or any single study.
- 4 of Chugai Pharmaceutical's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Celiac Disease is the condition Chugai Pharmaceutical studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Celiac Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Chugai Pharmaceutical pipeline card: 17 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.